



January 3, 2017

PTC Therapeutics to Present 2017 Corporate Update at the 35th Annual J.P. Morgan Healthcare Conference

SOUTH PLAINFIELD, N.J., Jan. 3, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a corporate update at the upcoming 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 7:30 am PT.

The presentation will be webcast live on the Events and Presentations page under the investors section of PTC Therapeutics' website at www.ptcbio.com. The presentation will be archived for two weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

About PTC Therapeutics, Inc.

PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA, or mRNA, molecule is copied from DNA through the transcription process. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information on the company, please visit our website www.ptcbio.com.

For More Information Please Contact:

Media:

Jane Baj
+1 (908) 912-9167
jbaj@ptcbio.com

Investors:

Emily Hill
+1 (908) 912-9327
ehill@ptcbio.com

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/ptc-therapeutics-to-present-2017-corporate-update-at-the-35th-annual-jp-morgan-healthcare-conference-300384705.html>

SOURCE PTC Therapeutics, Inc.

News Provided by Acquire Media